...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Reliability of Immunoglobulin G Antitoxoplasma Avidity Test and Effects of Treatment on Avidity Indexes of Infants and Pregnant Women
【24h】

Reliability of Immunoglobulin G Antitoxoplasma Avidity Test and Effects of Treatment on Avidity Indexes of Infants and Pregnant Women

机译：免疫球蛋白G抗弓形虫亲和力测试的可靠性以及治疗对婴儿和孕妇亲和力指数的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The immunoglobulin G antitoxoplasma avidity test (Vidas; BioMérieux) is an immunoenzymatic test useful for excluding acute infection after the onset of pregnancy. The avidity index (AI) is the ratio of the signal in a test sample washed with urea, which disrupts low-avidity complexes, to that washed without urea. An AI of >0.3 is taken to mean that infection had occurred more than 4 months ago. The increase of the AI with time and the influence of the different treatments given to pregnant women and their newborns were evaluated. A total of 59 pregnant women (271 sera) and their 60 neonates (199 sera) were tested from 1998 to 2002. There were five groups of women based on the type and duration of treatment given. Thirteen pregnant women (group 1) did not receive any treatment, 15 (group 2), 11 (group 3), and 17 (group 4) women received treatment with spiramycin (9 MIU/day) for 0.5 to 2, 2.5 to 5, and 5.5 to 8 months, respectively, and the last 3 women (group 5) received tritherapy (pyrimethamine-sulfonamide and spiramycin alternatively) for 1.5 to 2.5 months. All of the maternal sera collected in the first 6 months had an AI of <0.30, with a mean of 0.07 (range, 0.01 to 0.21). The increase was slow (0.02/month), and there was no significant difference when comparisons were made between the treatment groups. Neonates with proven maternofetal transmission had an increasing AI, unlike those without transmission. However, long-term therapy with pyrimethamine-sulfonamide, as opposed to treatment with spiramycin alone, was found to slow down the progression of the AI. An AI of >0.2 is sufficient to exclude acute infection in pregnant women. In neonates, it is not of major use to diagnose congenital infection; however, it could be a good indicator of compliance and efficacy of treatment of infected infants.
机译：免疫球蛋白G抗弓形虫亲和力测试（Vidas;BioMérieux）是一种免疫酶测试，可用于排除妊娠后的急性感染。亲和力指数（AI）是用尿素洗涤的测试样品中的信号与不使用尿素洗涤的信号之比，该信号破坏了低亲和力的复合物。 AI> 0.3表示感染已发生超过4个月前。评估了AI随时间的增加以及对孕妇及其新生儿进行不同治疗的影响。从1998年至2002年，共对59例孕妇（271血清）和60例新生儿（199血清）进行了检测。根据所给予治疗的类型和持续时间，分为5组妇女。 13名孕妇（第1组）未接受任何治疗，15名（第2组），11名（第3组）和17名（第4组）妇女接受了spiramycin（9 MIU /天）治疗，治疗时间为0.5至2、2.5至5分别为5.5和8个月，最后3名妇女（第5组）接受了1.5到2.5个月的三联疗法（乙胺嘧啶-磺酰胺和螺旋霉素）。前六个月收集的所有母体血清AI均<0.30，平均值为0.07（范围为0.01至0.21）。增加是缓慢的（0.02 /月），并且在治疗组之间进行比较时没有显着差异。事实证明，经胎儿生殖道传播的新生儿的AI增加，而没有经胎儿传播的新生儿。然而，与单独使用螺旋霉素治疗相比，使用乙胺嘧啶-磺酰胺进行长期治疗会减慢AI的进程。 AI> 0.2足以排除孕妇的急性感染。在新生儿中，它不是诊断先天性感染的主要方法。但是，它可能是感染婴儿治疗依从性和疗效的良好指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号